Novocure climbs after late-stage win for lung cancer therapy
Source: SeekingAlpha
2026-04-30 10:34:44 ET
More on NovoCure
- NovoCure Limited (NVCR) Q4 2023 Earnings Call Transcript
- NovoCure Limited 2023 Q4 - Results - Earnings Call Presentation
- NovoCure: Stay Cautious Amid Positive Signs
- NovoCure Q4 2023 Earnings Preview
- NovoCure Tumor Treating Fields accepted for FDA review
Read the full article on Seeking Alpha
For further details see:
Novocure climbs after late-stage win for lung cancer therapy
NovoCure Limited
NASDAQ: NVCR
NVCR Trading
28.92% G/L:
$15.20 Last:
3,202,896 Volume:
$13.36 Open:
NVCR Latest News
NVCR Stock Data
$1,170,211,701
105,800,576
0.07%
77
N/A
Medical Equipment & Supplies
Healthcare
JE
St. Helier
